Oculis
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $114.7Mattributed |
|---|---|
| Latest round | seed, $114.5M, 2025-08-15attributed |
| Founded | 2017 |
| Headquarters | Lausanne, Switzerland |
| Industry | bio |
| Stage | series-b+ |
| Website | oculis.com |
Oculis is a clinical-stage ophthalmology company developing topical and systemic treatments for serious eye conditions including diabetic macular edema, glaucoma, and dry-eye disease. Its OCS-01 dexamethasone eye drop uses a nanoparticle platform that delivers drug into the posterior segment without injection.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-08-15 | seed | $114.5M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Google Tag Manager, GSAP 3.12.5, Cloudflare Bot Management, Cookiebot, WP Engine, WP Rocket 3.21.3, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $114.5M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $114.7M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | oculis.com, read 2026-05-07 |
| Description | self-reported | oculis.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.